

Regimen Reference Order – THOR – brigatinib

ARIA: LUNG - [brigatinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Non-Small Cell Lung Cancer ALK-positive

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – THOR – brigatinib

Drug	Dose	CCMB Administration Guideline
Cycle 1		
Days 1 to 7		
brigatinib	90 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
Days 8 to 28		
brigatinib	180 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
Cycle 2 and Onwards		
Days 1 to 28		
brigatinib	180 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
brigatinib (ALUNBRIG®) available dosage strengths: 30 mg, 90 mg and 180 mg tablets		
Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

Cycle 1

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders
- CK and lipase as per Physician Orders
- Heart rate and blood pressure
- EKG at physician's discretion

Day 6 or 7

- Clinic nurse assessment by medical oncology nurse (monitor for signs and symptoms of interstitial lung disease/pneumonitis)

Day 15

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders
- CK and lipase as per Physician Orders
- Heart rate and blood pressure
- EKG at physician's discretion

Cycles 2 and 3

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders
- CK and lipase as per Physician Orders
- Heart rate and blood pressure

Day 15

- Liver enzymes and total bilirubin

Cycle 4 and Onwards

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and glucose as per Physician Orders
- CK and lipase as per Physician Orders
- Heart rate and blood pressure

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS TO PATIENT

- Patients should monitor blood pressure at home and record measurements on blood pressure log
 - Notify Medical Oncologist if systolic blood pressure is greater than 160 mmHg or diastolic blood pressure is greater than 100 mmHg
- Patients should be counseled on potential for vision changes and cognitive changes with brigatinib
- brigatinib can cause elevations in Creatine phosphokinase (CK). Patients should report any unexplained muscle pain, tenderness or weakness
- Patients should monitor for new or worsening respiratory symptoms (e.g. dyspnea, cough) especially during the first 7 days of treatment because of the risk of interstitial lung disease/pneumonitis
- Patients should use broad-spectrum sunscreen when going outdoors
- brigatinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on brigatinib

ADDITIONAL INFORMATION

- brigatinib can cause elevations in pancreatic enzymes and hepatic enzymes
- brigatinib can cause bradycardia
- brigatinib may cause hyperglycemia
- brigatinib will be dispensed by CCMB Pharmacy